SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Interim Results from RELY-ABLE®, the RE-LY® Extension Study, Provide Additional Clinical Evidence for the Safety of Pradaxa® (Dabigatran Etexilate Mesylate)